Basisstatistiken
| CIK | 1849296 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OKYO Pharma Limited
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) Ind |
|
| May 19, 2026 |
Exhibit 99.1 OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD ● Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease ● OKYO’s introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO London and New York, NY, |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| April 29, 2026 |
Exhibit 99.1 OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May ● Robert J. Dempsey, MBA, Chief Executive Officer, to present at Eyecelerator ● Raj Patil, PhD, Chief Scientific Officer, to present at ARVO London and New York, NY, April 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat |
|
| April 7, 2026 |
Exhibit 99.1 OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting London and New York, NY, April 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it will |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 19, 2026 |
OKYO Pharma Announces Director Acquires Shares Exhibit 99.1 OKYO Pharma Announces Director Acquires Shares London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired |
|
| March 19, 2026 |
OKYO Pharma Announces Chairman and Founder Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman and Founder Acquires Shares London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in whi |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 19, 2026 |
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chief Development Officer and Director Acquires Shares London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Develo |
|
| March 18, 2026 |
Exhibit 99.1 OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain London and New York, NY, March 18, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflamm |
|
| March 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| February 23, 2026 |
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress Exhibit 99.1 OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress London and New York, NY, February 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for pre |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| February 17, 2026 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-293145 Prospectus Supplement (To Prospectus Dated February 10, 2026) OKYO PHARMA LIMITED 10,815,000 Ordinary Shares We are offering 10,815,000 ordinary shares, no par value per ordinary share, pursuant to this prospectus supplement and the accompanying prospectus at a public offering price of $1.85 per ordinary share. Our ordinary shares are li |
|
| February 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| February 13, 2026 |
10,815,000 Shares OKYO Pharma Limited Ordinary Shares UNDERWRITING AGREEMENT Exhibit 1.1 Execution Version 10,815,000 Shares OKYO Pharma Limited Ordinary Shares UNDERWRITING AGREEMENT February 12, 2026 PIPER SANDLER & CO. 350 North 5th St., Suite 1000 Minneapolis, Minnesota 55401 As Representative of the several Underwriters named in Schedule I hereto Ladies and Gentlemen: OKYO Pharma Limited, a public limited liability company incorporated under the laws of Guernsey (the |
|
| February 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| February 13, 2026 |
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares Exhibit 99.1 OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares London and New York, NY, February 12, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offeri |
|
| February 13, 2026 |
Exhibit 99.3 |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| February 12, 2026 |
OKYO Pharma Announces Public Offering of Ordinary Shares Exhibit 99.1 OKYO Pharma Announces Public Offering of Ordinary Shares London and New York, NY, February 12, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwri |
|
| February 12, 2026 |
Subject to completion, dated February 12, 2026 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 10, 2026 |
Exhibit 99.1 OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer ● Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease ● Dr. Mantelli will lead the clinical and regulatory strategy to advance th |
|
| February 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| February 6, 2026 |
February 6, 2026 Robert J. Dempsey Chief Executive Officer and Director OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB Re: OKYO Pharma Limited Registration Statement on Form F-3 Filed February 2, 2026 File No. 333-293145 Dear Robert J. Dempsey: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 |
|
| February 6, 2026 |
OKYO Pharma LTD. Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB OKYO Pharma LTD. Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB VIA EDGAR February 6, 2026 Securities and Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, D.C. 20549 Re: OKYO Pharma Ltd. Registration Statement on Form F-3 Filed February 2, 2026 SEC File No. 333-293145 To Whom It May Concern: Pursuant to Rule 461 under the Securities Act of 1933, as |
|
| February 2, 2026 |
As filed with the Securities and Exchange Commission on February 2, 2026 As filed with the Securities and Exchange Commission on February 2, 2026 Registration No. |
|
| February 2, 2026 |
Exhibit 107 Calculation of Filing Fee Table FORM F-3 (Form Type) OKYO PHARMA LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary Shares, no par value (1) (1 ) (1 ) (1 ) (1 ) (1 ) Fees to Be Paid Other Warrants (1) (1 ) (1 ) (1 ) (1 ) (1 ) Fees to Be Paid Other Units(2) (1) (1 ) (1 ) (1 ) (1 ) (1 ) Fees to Be Paid Unallocated (Universal) Shelf Unallocated (Universal Shelf) 457(o) (1 ) (1 ) $ 200,000,000 (1) $ 0. |
|
| January 30, 2026 |
Exhibit 99.1 OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting London and New York, NY, January 30, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that |
|
| January 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| January 30, 2026 |
Exhibit 99.2 OKYO Pharma Limited Chairman’s statement Dear Shareholders, I am pleased to present the interim results for OKYO Pharma Limited for the six-month period ended 30 September 2025. This period has been marked by significant progress in our clinical development programs, particularly with our lead candidate, urcosimod, for the treatment of neuropathic corneal pain (NCP), a condition with |
|
| January 30, 2026 |
OKYO Pharma Interim Results for the Six Months Ended 30 September 2025 Exhibit 99.1 OKYO Pharma Interim Results for the Six Months Ended 30 September 2025 London and New York, NY, January 30, 2026 – OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, has today filed its interim results for the six months ended 30 Septe |
|
| January 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| January 28, 2026 |
Exhibit 99.1 OKYO Pharma Announces Successful Type C Meeting with the FDA FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size, and development approach London and New York, NY, January 28, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| January 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| January 23, 2026 |
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain Exhibit 99.1 FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain London and New York, NY, January 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that the U.S. Food and Drug |
|
| January 5, 2026 |
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer Exhibit 99.1 OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer ● Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise ● Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board London and New York, NY, January 5, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-st |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2026 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| December 19, 2025 |
OKYO Pharma to Ring the Opening Bell at Nasdaq Exhibit 99.1 OKYO Pharma to Ring the Opening Bell at Nasdaq London and New York, NY, December 19, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chai |
|
| December 15, 2025 |
OKYO Pharma Announces Chairman and Founder Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman and Founder Acquires Shares London and New York, NY, December 15, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today an |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| December 11, 2025 |
Exhibit 99.1 OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain ● Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group ● These findings suggest that urcosimod may have a positive impact on corneal nerve health in patie |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| December 3, 2025 |
OKYO Pharma Announces Chairman and Founder Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman and Founder Acquires Shares London and New York, NY, December 3, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today ann |
|
| November 21, 2025 |
OKYO Pharma Announces Chairman and Founder Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman and Founder Acquires Shares London and New York, NY, November 21, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today an |
|
| November 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| November 18, 2025 |
OKYO Pharma to Present at OIS XV in San Diego Exhibit 99.1 OKYO Pharma to Present at OIS XV in San Diego London and New York, NY, November 18, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Gary S |
|
| November 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| October 29, 2025 |
OKYO Pharma to Present at BIO-Europe 2025 in Vienna Exhibit 99.1 OKYO Pharma to Present at BIO-Europe 2025 in Vienna London and New York, NY, October 29, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that Gary S. Jacob, Ph.D., Chi |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| October 16, 2025 |
OKYO Pharma Announces Chairman and Founder Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman and Founder Acquires Shares London and New York, NY, October 16, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today ann |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| September 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive offic |
|
| September 22, 2025 |
Exhibit 99.1 OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain London and New York, NY, September 22, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often |
|
| August 12, 2025 |
OKYO Pharma Limited CLAWBACK POLICY Exhibit 97 OKYO Pharma Limited CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this Clawback |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI |
|
| August 12, 2025 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with OKYO Pharma Ltd’s Annual Report on Form 20-F/A for the fiscal year ended March 31, 2025 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. G |
|
| August 12, 2025 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F/A of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the |
|
| August 12, 2025 |
Exhibit 12.1 CERTIFICATION I, Gary Jacob, certify that: 1. I have reviewed this annual report on Form 20-F/A of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the |
|
| August 12, 2025 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with OKYO Pharma Ltd’s Annual Report on Form 20-F/A for the fiscal year ended March 31, 2025 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. K |
|
| July 18, 2025 |
Exhibit 12.1 CERTIFICATION I, Gary Jacob, certify that: 1. I have reviewed this annual report on Form 20-F of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the pe |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| July 18, 2025 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with OKYO Pharma Ltd’s Annual Report on Form 20-F for the fiscal year ended March 31, 2025 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Gar |
|
| July 18, 2025 |
OKYO PHARMA LTD INSIDER TRADING POLICY Exhibit 19.1 OKYO PHARMA LTD INSIDER TRADING POLICY 1. PURPOSE This Insider Trading Policy (this “Policy”) states the policy with respect to transactions in the securities of OKYO Pharma Ltd. (the “Company”), and the handling of confidential information about the Company and other companies with which the Company does business. The Company’s Board of Directors has adopted this Policy to promote co |
|
| July 18, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors of OKYO Pharma Ltd: We consent to the incorporation by reference of our report dated July 18, 2025 with respect to the consolidated balance sheet for the year ended March 31, 2025 and the related consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity for the period |
|
| July 18, 2025 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with OKYO Pharma Ltd’s Annual Report on Form 20-F for the fiscal year ended March 31, 2025 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Kee |
|
| July 18, 2025 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the p |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| July 17, 2025 |
Exhibit 99.1 OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain London and New York, NY, July 17, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe n |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| July 16, 2025 |
Exhibit 99.1 OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain ● After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment. ● Urcosimod (0.05%) demonstrated a marke |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| June 11, 2025 |
Up to $15,500,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-272516 Prospectus Supplement (To Prospectus dated June 14, 2023) Up to $15,500,000 Ordinary Shares We previously entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Agent” or “B. Riley”), relating to our ordinary shares, no par value per share, offered by this prospectus supplement and |
|
| June 11, 2025 |
OKYO Pharma to Present at the Bio International Convention Exhibit 99.1 OKYO Pharma to Present at the Bio International Convention London and New York, NY, June 11, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jaco |
|
| May 19, 2025 |
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit Exhibit 99.1 OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit London and New York, NY, May 19, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) Ind |
|
| May 1, 2025 |
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain Exhibit 99.1 FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain London and New York, NY, May 1, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, a |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) Ind |
|
| April 30, 2025 |
Exhibit 99.1 OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain ● Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial. ● OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now comp |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 31, 2025 |
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod Exhibit 99.1 OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod ● Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability ● Urcosimod stable in single-use ampoules for more than 2½ years ● FDA requires drug to show long-term shelf stability for approval ● Daily administration to patients via ampoules can minimize risk of contamination |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 10, 2025 |
Exhibit 99.1 OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain London and New York, NY, March 10, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory dry ey |
|
| February 12, 2025 |
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod Exhibit 99.1 OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod London and New York, NY, February 12, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-bi |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| January 31, 2025 |
OKYO Pharma Announces Chairman and CEO Acquire Shares Exhibit 99.1 OKYO Pharma Announces Chairman and CEO Acquire Shares London and New York, NY, January 31, 2025 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| January 29, 2025 |
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter Exhibit 99.1 OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter London and New York, NY, January 29, 2025 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry e |
|
| January 29, 2025 |
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter Exhibit 99.2 OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter London and New York, NY, January 29, 2025 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry e |
|
| January 22, 2025 |
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding Exhibit 99.1 OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding London and New York, NY, January 22, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dol |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2025 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| November 26, 2024 |
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference Exhibit 99.1 OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference London and New York, NY, November 26, 2024. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| October 30, 2024 |
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference Exhibit 99.1 OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference London and New York, NY, October 30, 2024. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye dise |
|
| October 23, 2024 |
Exhibit 99.1 OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain ● OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial ● The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients ● OK-101 is the first IND granted |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| October 16, 2024 |
Exhibit 99.1 OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain ● Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease ● OKYO is the first company to have an IND application granted by the FDA for NCP ● The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked s |
|
| September 10, 2024 |
OKYO Pharma Announces Chairman Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman Acquires Shares London and New York, NY, September 10, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive offic |
|
| September 5, 2024 |
OKYO Pharma Announces Chairman Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman Acquires Shares London and New York, NY, September 5, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive offic |
|
| August 27, 2024 |
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease Exhibit 99.1 OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease London and New York, NY, August 27, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 23, 2024 |
OKYO Pharma Announces Chairman Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman Acquires Shares London and New York, NY, August 23, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular co |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 23, 2024 |
OKYO Pharma CEO Interview to Air on Bloomberg TV Exhibit 99.1 OKYO Pharma CEO Interview to Air on Bloomberg TV London and New York, NY, August 23, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 21, 2024 |
OKYO Pharma Announces Chairman Acquires Shares Exhibit 99.1 OKYO Pharma Announces Chairman Acquires Shares London and New York, NY, August 21, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular co |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 15, 2024 |
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference Exhibit 99.1 OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference London and New York, NY, August 15, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neu |
|
| August 13, 2024 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the p |
|
| August 13, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm The Board of Directors of OKYO Pharma Limited We hereby consent to the incorporation by reference within the Form 20-F (to be filed on or about August 13, 2024) of our report dated August 15, 2022 with respect to the consolidated balance sheet for the year ended March 31, 2022 and the related consolidated statements of operation |
|
| August 13, 2024 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with OKYO Pharma Ltd’s Annual Report on Form 20-F for the fiscal year ended March 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Gar |
|
| August 13, 2024 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with OKYO Pharma Ltd’s Annual Report on Form 20-F for the fiscal year ended March 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Kee |
|
| August 13, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm The Board of Directors of OKYO Pharma Ltd: We consent to the incorporation by reference of our report dated August 13, 2024 with respect to the consolidated balance sheet for the year ended March 31, 2024 and the related consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity for the peri |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 |
|
| August 13, 2024 |
Exhibit 12.1 CERTIFICATION I, Gary Jacob, certify that: 1. I have reviewed this annual report on Form 20-F of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the pe |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 6, 2024 |
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use Exhibit 99.1 OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use London and New York, NY, August 6, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-41386 NOTIFICATION OF LATE FILING ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| July 11, 2024 |
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 Exhibit 99.1 OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 ● Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 ● OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical |
|
| July 10, 2024 |
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease Exhibit 99.1 OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease — Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial — Conjunctival staining and ocular pain represent potential co-primary endpoint |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| July 10, 2024 |
Exhibit 99.1 |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) Ind |
|
| May 8, 2024 |
OKYO Pharma Announces Participation in May 2024 Investor Conferences Exhibit 99.1 OKYO Pharma Announces Participation in May 2024 Investor Conferences London and New York, NY, May 8, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain ( |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| April 30, 2024 |
Exhibit 99.1 OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) London and New York, NY, April 30, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inf |
|
| April 9, 2024 |
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 Exhibit 99.1 OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 London and New York, NY, April 8, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| April 4, 2024 |
Exhibit 99.1 |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-41386 OKYO Pharma Ltd. (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of principal executive office) Indicate by c |
|
| April 2, 2024 |
Exhibit 99.1 OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery London and New York, NY, April 2, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 29, 2024 |
London and New York, NY, March 29, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), Exhibit 99.1 London and New York, NY, March 29, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announces its i |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 22, 2024 |
Exhibit 99.1 OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 ● Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial. ● Conjunctival Staining improved as early as day 2 |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 21, 2024 |
Exhibit 99.1 OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial -Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- London and New York, NY, March 21, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular th |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) I |
|
| March 20, 2024 |
Exhibit 99.1 OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event -Phase 2 OK-101 efficacy data to be released March 22, 2024- London and New York, NY, March 20, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disea |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| February 9, 2024 |
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain Exhibit 99.1 OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain ● OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need ● The initial trial of OK-101 to treat NCP is designed as a randomized, placebo-controlled, double-masked Phase 2 |
|
| January 31, 2024 |
Exhibit 99.1 OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board London and New York, NY, January 31, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| January 8, 2024 |
Exhibit 99.1 OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease ● Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosing ● Statistically significant improvement was observed in |
|
| January 5, 2024 |
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 Exhibit 99.1 OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 London and New York, NY, January 5, 2024. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular c |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2024 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of principal executive office) Indicate by |
|
| December 21, 2023 |
OKYO PHARMA LIMITED Ordinary Shares (no par value) At Market Issuance Sales Agreement Exhibit 1.1 Execution Version OKYO PHARMA LIMITED Ordinary Shares (no par value) At Market Issuance Sales Agreement December 20, 2023 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: OKYO Pharma Limited, a public limited liability company incorporated under the laws of Guernsey (the “Company”), confirms its agreement (this “Agreement”) with B. Riley Se |
|
| December 20, 2023 |
Up to $4,000,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-272516 Prospectus Supplement (To Prospectus dated June 14, 2023) Up to $4,000,000 Ordinary Shares We have entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Agent” or “B. Riley”), relating to our ordinary shares, no par value per share, offered by this prospectus supplement and the ac |
|
| December 18, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-272516 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 14, 2023) 544,800 Ordinary Shares We are offering on a “reasonable best efforts” basis 400,000 ordinary shares, no par value per ordinary share, pursuant to this prospectus supplement and the accompanying prospectus at a public offering price of $1.50 per ordinary share. These securities ar |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of principal executive office) Indicate by |
|
| December 18, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December , 2023, is by and among OKYO Pharma Limited, a non-cellular company limited by shares incorporated under the Companies (Guernsey) Law 2008 (the “Company”), and the buyers identified on the signature pages hereto (the “Buyers”). RECITALS A. The Buyers, severally and not jointly, wi |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| December 4, 2023 |
Exhibit 99.1 OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit ● Top-line Efficacy and Safety Data on Track for Release in December 2023 London and New York, NY, December 4, 2023. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of i |
|
| November 29, 2023 |
Exhibit 99.1 |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of principal executive office) Indicate by |
|
| November 1, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of October , 2023, is by and among OKYO Pharma Limited, a non-cellular company limited by shares incorporated under the Companies (Guernsey) Law 2008 (the “Company”), and the buyers identified on the signature pages hereto (the “Buyers”). RECITALS A. The Buyers, severally and not jointly, wis |
|
| October 31, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-272516 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 14, 2023) 3,859,267 Ordinary Shares We are offering on a “reasonable best efforts” basis 1,092,600 ordinary shares, no par value per ordinary share, pursuant to this prospectus supplement and the accompanying prospectus at a public offering price of $1.50 per ordinary share. These securitie |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| October 31, 2023 |
OKYO Pharma Announces $5.84 Million cash raise and payables reduction Exhibit 99.1 OKYO Pharma Announces $5.84 Million cash raise and payables reduction ● Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share ● Simultaneous extinguishment of $4.20M of payables by issuing 2,766,667 ordinary shares, at the offering price of $1.50 per ordinary share, materially reducing current payables London a |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| October 10, 2023 |
Exhibit 99.1 OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”) ● OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP. ● Second clinical indication for OK-101 which is curre |
|
| October 5, 2023 |
Exhibit 99.1 OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (“DED”) ● Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial. ● The dropout rate is 5.4% and unr |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| September 15, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-272516 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 14, 2023) 2,666,670 Ordinary Shares We are offering on a “reasonable best efforts” basis 2,666,670 ordinary shares, no par value per ordinary share, pursuant to this prospectus supplement and the accompanying prospectus at a public offering price of $1.50 per ordinary share. These securitie |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive offic |
|
| September 15, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 14, 2023, is by and among OKYO Pharma Limited, a non-cellular company limited by shares incorporated under the Companies (Guernsey) Law 2008 (the “Company”), and the buyers identified on the signature pages hereto (the “Buyers”). RECITALS A. The Buyers, severally and not jointly, |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of principal executive office) Indicate b |
|
| September 15, 2023 |
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares Exhibit 99.1 OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares London and New York, NY – September 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the closing of its previously announced Company best effo |
|
| September 14, 2023 |
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares Exhibit 99.1 OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares London and New York, NY – September 14, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the pricing of a Company best efforts registered direct o |
|
| September 14, 2023 |
OKYO Pharma Limited Announces Withdrawal of Public Offering Exhibit 99.1 OKYO Pharma Limited Announces Withdrawal of Public Offering LONDON and NEW YORK, September 14, 2023 — OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced the withdrawal of its |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive offic |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive offic |
|
| September 13, 2023 |
OKYO Pharma Announces Public Offering of Ordinary Shares Exhibit 99.1 OKYO Pharma Announces Public Offering of Ordinary Shares London and New York, NY – September 13, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the |
|
| September 13, 2023 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 13, 2023 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive offic |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive offic |
|
| September 8, 2023 |
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease Exhibit 99.1 OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease ● Full enrollment achieved on September 6th with a total of 240 patients enrolled in study ● Top-line data planned for release in December 2023 ● Phase 2 trial is designed as a potential registration trial, with pre-specified primary efficacy endpoints covering both a sign and symptom of dry |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 30, 2023 |
Exhibit 99.1 OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”) ● Full enrollment anticipated by first week of September ● OKYO on schedule to release top-line data before end of 2023 ● Phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED Lond |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 29, 2023 |
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule Exhibit 99.1 OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule New York and London, August 29, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced |
|
| August 25, 2023 |
Exhibit 12.1 CERTIFICATION I, Gary Jacob, certify that: 1. I have reviewed this annual report on Form 20-F/A of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES |
|
| August 25, 2023 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F/A of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the |
|
| August 15, 2023 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with OKYO Pharma Ltd’s Annual Report on Form 20-F for the fiscal year ended March 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Kee |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) |
|
| August 15, 2023 |
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023 Exhibit 99.1 OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023 London and New York, NY, August 15 2023 – OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today announced financial results fo |
|
| August 15, 2023 |
Exhibit 12.2 CERTIFICATION I, Keeren Shah, certify that: 1. I have reviewed this annual report on Form 20-F of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the p |
|
| August 15, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm The Board of Directors of OKYO Pharma Ltd: We consent to the incorporation by reference of our report dated August 14, 2023 with respect to the consolidated balance sheet for the year ended March 31, 2023 and the related consolidated statement of operations and comprehensive loss, cash flows and shareholders’ equity for the peri |
|
| August 15, 2023 |
Exhibit 12.1 CERTIFICATION I, Gary Jacob, certify that: 1. I have reviewed this annual report on Form 20-F of OKYO Pharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the pe |
|
| August 15, 2023 |
Exhibit 16.1 30 Old Bailey London EC4M 7AU Tel: +44 (0)20 7063 4000 www.mazars.co.uk Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Date: August 14, 2023 Dear Commissioners: Re: OKYO Pharma Limited Commission File Number 0001849296 We have read the Item 16F of Form 20-F of OKYO Pharma Limited dated August 14, 2023, which discusses the resignation of Mazars LLP as that |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 |
|
| August 15, 2023 |
Exhibit 15.1 30 Old Bailey London EC4M 7AU Tel: +44 (0)20 7063 4000 www.mazars.co.uk Consent of Independent Registered Public Accounting Firm The Board of Directors of OKYO Pharma Limited, We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (File No. 333-272516) of our report dated August 15, 2022 with respect to the consolidated balance sheet for the year |
|
| August 15, 2023 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with OKYO Pharma Ltd’s Annual Report on Form 20-F for the fiscal year ended March 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Gar |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-41386 NOTIFICATION OF LATE FILING ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| July 31, 2023 |
OKYO Pharma Limited Announces Withdrawal of Public Offering Exhibit 99.1 OKYO Pharma Limited Announces Withdrawal of Public Offering LONDON and NEW YORK, July 31, 2023 — OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced the withdrawal of its propo |
|
| July 28, 2023 | ||
| July 28, 2023 |
The date of this prospectus supplement is July , 2023. Table of Contents Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration No. 333-272516 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| July 28, 2023 |
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares Exhibit 99.1 OKYO Pharma Announces Proposed Public Offering of Ordinary Shares London and New York, NY – July 28, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it intends |
|
| July 28, 2023 |
OKYO Pharma Limited Receives Nasdaq Deficiency Notice Exhibit 99.1 OKYO Pharma Limited Receives Nasdaq Deficiency Notice New York, July 28, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it received a deficiency letter from th |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| July 28, 2023 |
Exhibit 99.1 OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center ● OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP ● Second clinical indication for OK-101 wh |
|
| July 27, 2023 |
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer Exhibit 99.1 OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer LONDON and NEW YORK, July 27, 2023— OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that it has appointed W |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) In |
|
| June 15, 2023 |
18,406,026 Ordinary Shares OKYO Pharma Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-272005 PROSPECTUS 18,406,026 Ordinary Shares OKYO Pharma Limited This prospectus relates to the resale from time to time in one or more offerings by the selling shareholders named herein with respect to an aggregate of 18,406,026 ordinary shares held by the selling shareholders identified herein. Holders of all such ordinary shares are identifi |
|
| June 12, 2023 |
OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB June 12, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: OKYO Pharma Limited Registration Statement on Form F-3 June 8, 2023 File No. 333-272516 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under |
|
| June 12, 2023 |
United States securities and exchange commission logo June 12, 2023 Gary Jacob, Ph. |
|
| June 12, 2023 |
OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB June 12, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: OKYO Pharma Limited Registration Statement on Form F-1/A June 9, 2023 File No. 333-272005 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations unde |
|
| June 9, 2023 |
As filed with the Securities and Exchange Commission on June 9, 2023. As filed with the Securities and Exchange Commission on June 9, 2023. Registration Statement No. 333-272005 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OKYO Pharma Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) OKYO PHARMA LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary Shares, no par value (1) (1) (1) (1) (1) (1) Fees to Be Paid Other Warrants (1) (1) (1) (1) (1) (1) Fees to Be Paid Other Units(2) (1) (1) (1) (1) (1) (1) Fees to Be Paid Unallocated (Universal Shelf) Unallocated (Universal Shelf) 457(o) (1) (1) $ 100,000,000 (1) $ 0. |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023. As filed with the Securities and Exchange Commission on June 8, 2023. Registration Statement No. 333-272005 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OKYO Pharma Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English |
|
| June 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) OKYO PHARMA LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of each Class of Securities to be Registered Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Ordinary Shares, no par value(4) 457(c) 18,406,026 $ 0. |
|
| June 6, 2023 |
Exhibit 99.1 OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease ● Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain component ● Top-line data from trial anticipated in Q4, 2023 London and New York, NY, June 6, 2023 – OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmol |
|
| June 6, 2023 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal ex |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OKYO PHARMA LIMITED (Exact name of registrant as specified in its charter) Guernsey Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification N |
|
| June 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) OKYO PHARMA LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of each Class of Securities to be Registered Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Ordinary Shares, no par value(4) 457(c) 10,153,740 $ 0. |
|
| June 2, 2023 |
Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212. |
|
| June 2, 2023 |
As filed with the Securities and Exchange Commission on June 2, 2023. As filed with the Securities and Exchange Commission on June 2, 2023. Registration Statement No. 333-272005 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OKYO Pharma Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English |
|
| May 30, 2023 |
United States securities and exchange commission logo May 30, 2023 Gary S. Jacob, Ph.D. Chief Executive Officer OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB Re: OKYO Pharma Limited Registration Statement on Form F-1 Filed May 17, 2023 File No. 333-272005 Dear Gary S. Jacob: We have limited our review of your registration statement to those issues we have addresse |
|
| May 22, 2023 |
OKYO Pharma Limited (“OKYO” or “Company”) London Stock Exchange Delisting Exhibit 99.1 22 May 2023 OKYO Pharma Limited (“OKYO” or “Company”) London Stock Exchange Delisting Further to the Dealing Announcement published by the FCA this morning, the board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), confirm the cancellation of its ordinary shares of no par value each (“Ordinary Shares”) from listing on the standard segment of the FCA’s Official List and |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) Ind |
|
| May 19, 2023 |
Exhibit 99.1 OKYO PHARMA LIMITED ADS Program collapse - Commencement of trading of new ordinary shares on The Nasdaq Capital Market LONDON and NEW YORK, May 19, 2023 — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) hereby announces that following the implementation of the share capital consolidation and collapse of its ADS program, it is expected that new OKYO ordinary shares will be listed on The |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2023 Commission File Number: 001-41386 OKYO Pharma LTD (Exact Name of Registrant as Specified in Its Charter) 9th Floor 107 Cheapside London EC2V 6DN (Address of registrant’s principal executive office) Ind |
|
| May 17, 2023 |
As filed with the Securities and Exchange Commission on May 17, 2023. As filed with the Securities and Exchange Commission on May 17, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OKYO Pharma Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) OKYO Pharma Limited Mar |
|
| May 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) OKYO PHARMA LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of each Class of Securities to be Registered Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Ordinary Shares, no par value(4) 457 (c) 10,153,281 $ 0. |
|
| May 15, 2023 |
OKYO Pharma Limited (“OKYO” or “Company”) Change of Record Time and Last Day of Dealings Exihibit 99.1 OKYO Pharma Limited (“OKYO” or “Company”) Change of Record Time and Last Day of Dealings London, May 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, previously ann |
